Glaukos Co. (NYSE:GKOS) CFO Sells $162,396.80 in Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $103.67 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 52 week low of $88.16 and a 52 week high of $163.71. The firm has a market cap of $5.86 billion, a PE ratio of -36.12 and a beta of 0.99. The firm’s fifty day moving average is $131.61 and its 200-day moving average is $135.83.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Sell-side analysts predict that Glaukos Co. will post -1.08 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GKOS. Charles Schwab Investment Management Inc. lifted its holdings in Glaukos by 47.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock valued at $83,609,000 after buying an additional 207,338 shares during the period. Algert Global LLC boosted its position in shares of Glaukos by 162.4% during the 3rd quarter. Algert Global LLC now owns 13,260 shares of the medical instruments supplier’s stock valued at $1,728,000 after purchasing an additional 8,206 shares in the last quarter. Harvest Fund Management Co. Ltd grew its stake in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares during the period. The Manufacturers Life Insurance Company grew its stake in Glaukos by 2.3% during the third quarter. The Manufacturers Life Insurance Company now owns 28,343 shares of the medical instruments supplier’s stock worth $3,693,000 after purchasing an additional 632 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in Glaukos by 186.9% in the third quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock worth $1,788,000 after purchasing an additional 8,942 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wells Fargo & Company lifted their price target on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. UBS Group initiated coverage on Glaukos in a research report on Friday, December 6th. They issued a “buy” rating and a $182.00 target price on the stock. Stifel Nicolaus increased their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Piper Sandler restated an “overweight” rating and issued a $180.00 price target (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Finally, Stephens upgraded shares of Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $163.25.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.